BMY — Bristol-Myers Squibb Co Share Price
Last trade - 00:00- $94.33bn
- $132.31bn
- $48.30bn
- 97
- 79
- 69
- 96
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 7.21 | ||
| PEG Ratio (f) | 0.33 | ||
| EPS Growth (f) | 27.89% | ||
| Dividend Yield (f) | 5.43% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 5.42 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | 7.21 | ||
| Price to Sales | 1.98 | ||
| EV to EBITDA | 8.23 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 11.69% | ||
| Return on Equity | 31.99% | ||
| Operating Margin | 16.78% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 42,518 | 46,385 | 46,159 | 45,006 | 48,300 | 46,229.28 | 42,991.03 | 13.06% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | -71.48 | +297.48 | -17.67 | +20.08 | -10.65 | +101.24 | -9.98 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bristol-Myers Squibb Company is a global biopharmaceutical company. It is engaged in the discovery, development and delivery of transformational medicines for patients facing serious diseases in areas: oncology, hematology, immunology, cardiovascular, neuroscience and other areas. Its platforms comprise chemically synthesized or small molecule drugs, including protein degraders; drugs produced from biological processes, called biologics; ADCs, CAR-T cell therapies, and radiopharmaceutical therapeutics. Small molecule drugs are typically administered orally in the form of a tablet or capsule, although other drug delivery mechanisms are also used. Biologics are typically administered through injections or by intravenous infusion. CAR-T cell therapies are administered by intravenous infusion. Its growth portfolio includes Opdivo, Opdivo Qvantig, Orencia, Yervoy, Reblozyl, Opdualag, and others. Its legacy portfolio includes Eliquis, Revlimid, Pomalyst/Imnovid, Sprycel and Abraxane.
Directors
- Giovanni Caforio CHM (56)
- David Elkins CFO (52)
- Ann Powell CHO (55)
- Sandra Leung EVP (60)
- Christopher Boerner EVP (50)
- Samit Hirawat EVP (52)
- Elizabeth Mily EVP (53)
- Louis Schmukler EVP (65)
- Rupert Vessey EVP (56)
- Paul von Autenried SVP (59)
- Adam Dubow SVP (54)
- Karen Santiago SVP (50)
- Joseph Eid SVP (53)
- Theodore Samuels LED (66)
- Manuel Medina DRC (53)
- Peter Arduini IND (56)
- Julia Haller IND (66)
- Paula Price IND (60)
- Derica Rice IND (56)
- Gerald Storch IND (64)
- Karen Vousden IND (63)
- Phyllis Yale IND (63)
- Last Annual
- December 31st, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- August 11th, 1933
- Public Since
- March 17th, 1980
- No. of Shareholders
- 29,685
- No. of Employees
- 34,100
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- New York Stock Exchange
- Shares in Issue
- 2,035,080,810
- Address
- Route 206 And Province Line Road, PRINCETON, 08543
- Web
- https://www.bms.com
- Phone
- +1 6092524621
- Auditors
- Deloitte & Touche LLP
Latest News for BMY
Upcoming Events for BMY
Dividend For BMYm.BA - 0.2067 USD
Dividend For BMYB34.SA - 3.3956 BRL
Dividend For BMY.N - 0.6200 USD
Q2 2025 Bristol-Myers Squibb Co Earnings Call
Q2 2025 Bristol-Myers Squibb Co Earnings Release
Dividend For BMYMP.PK - 0.5000 USD
Q3 2025 Bristol-Myers Squibb Co Earnings Call
Q3 2025 Bristol-Myers Squibb Co Earnings Release
Similar to BMY
Abbvie
New York Stock Exchange
Bausch Health Companies
New York Stock Exchange
Bristol-Myers Squibb Co
New York Stock Exchange
Cardinal Health
New York Stock Exchange
Dr Reddy's Laboratories
New York Stock Exchange
FAQ
As of Today at 19:43 UTC, shares in Bristol-Myers Squibb Co are trading at $46.35. This share price information is delayed by 15 minutes.
Shares in Bristol-Myers Squibb Co last closed at $46.35 and the price had moved by +11.66% over the past 365 days. In terms of relative price strength the Bristol-Myers Squibb Co share price has underperformed the S&P500 Index by -1.23% over the past year.
The overall consensus recommendation for Bristol-Myers Squibb Co is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe Bristol-Myers Squibb Co dividend yield is 5.22% based on the trailing twelve month period.
Last year, Bristol-Myers Squibb Co paid a total dividend of $2.42, and it currently has a trailing dividend yield of 5.22%.Looking ahead, shares in Bristol-Myers Squibb Co are due to go ex-dividend on 2025-07-03 and the next dividend pay date is 2025-08-01.
Bristol-Myers Squibb Co are due to go ex-dividend on 2025-07-03 and the next dividend pay date is 2025-08-01. The historic dividend yield on Bristol-Myers Squibb Co shares is currently 5.22%.
To buy shares in Bristol-Myers Squibb Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $46.35, shares in Bristol-Myers Squibb Co had a market capitalisation of $94.33bn.
Here are the trading details for Bristol-Myers Squibb Co:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: BMY
Based on an overall assessment of its quality, value and momentum Bristol-Myers Squibb Co is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Bristol-Myers Squibb Co is $54.87. That is 18.38% above the last closing price of $46.35.
Analysts covering Bristol-Myers Squibb Co currently have a consensus Earnings Per Share (EPS) forecast of $6.76 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bristol-Myers Squibb Co. Over the past six months, its share price has underperformed the S&P500 Index by -23.11%.
As of the last closing price of $46.35, shares in Bristol-Myers Squibb Co were trading -14.3% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Bristol-Myers Squibb Co PE ratio based on its reported earnings over the past 12 months is 7.21. The shares last closed at $46.35.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Bristol-Myers Squibb Co's management team is headed by:
- Giovanni Caforio - CHM
- David Elkins - CFO
- Ann Powell - CHO
- Sandra Leung - EVP
- Christopher Boerner - EVP
- Samit Hirawat - EVP
- Elizabeth Mily - EVP
- Louis Schmukler - EVP
- Rupert Vessey - EVP
- Paul von Autenried - SVP
- Adam Dubow - SVP
- Karen Santiago - SVP
- Joseph Eid - SVP
- Theodore Samuels - LED
- Manuel Medina - DRC
- Peter Arduini - IND
- Julia Haller - IND
- Paula Price - IND
- Derica Rice - IND
- Gerald Storch - IND
- Karen Vousden - IND
- Phyllis Yale - IND